Categories Earnings, Health Care

Cancer drugs boost AstraZeneca results in Q1

Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter of top line growth. Product sales for the quarter jumped 14% to $5.46 billion, without taking into account the impact of currency fluctuations.

Product sales were primarily boosted by the oncology segment, where sales improved 59%, with particular strength in emerging markets including China.

AstraZeneca Product Sales Mix

Total revenue grew 11% to $5.49 billion, surpassing analysts’ projection of $5.27 billion. Core EPS doubled to 89 cents per share, beating the consensus estimate by 46 cents.

Lung Cancer drug Tagrisso was the best selling product during the quarter. Sale of this drug almost doubled to $630 million and accounted for 12% of its total product sales.

AstraZeneca product sales growth by segment

CEO Pascal Soriot said, “Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. In Oncology, Tagrisso, Imfinzi, and Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta, and Fasenra also grew strongly.”

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

“The recently-announced collaboration with Daiichi Sankyo also broadened an exciting Oncology portfolio with a potentially-transformative cancer treatment that could benefit patients around the world,” he added.

Outlook

The British-Swedish biopharmaceutical company revised its guidance following the solid results. The company now expects full-year 2019 product sales in a high single-digit percentage increase. Core EPS is projected in the range of $3.50 to $3.70.

AZN shares were down 1.4% during pre-market trading on Friday. The stock has gained 2.6% in the year-to-date period.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top